Drug Caucus Hearing on Barriers to Cannabidiol Research

The hearing will address the complexities involved with conducting research on cannabidiol, a Schedule I substance, as well as its potential medical benefits and risks in treating serious illnesses such as intractable epilepsy.

Webcast starts at 18:45

Senator Grassley's Statement | Senator Feinstein's Statement

Witnesses:

Panel One:      

Mr. Joseph Rannazzisi (Testimony)
Deputy Assistant Administrator of Drug Diversion with the Drug Enforcement Administration (DEA), Washington, D.C.

Dr. Douglas Throckmorton (Testimony)
Deputy Director for the Center for Drug Evaluation and Research, Food and Drug Administration, Washington, D.C.

Dr. Nora Volkow (Testimony)
Director, National Institute on Drug Abuse, Washington, D.C.

Panel Two:

Dr. John “Brad” Ingram (Testimony)
Child Neurologist, University of Mississippi Medical Center, Jackson, Mississippi

Dr. Tom Minahan (Testimony)
Emergency Room Physician, Arrowhead Regional Medical Center, Colton, California

Dr. Kevin Sabet (Testimony)
Co-Founder, Project SAM (Smart Approaches to Marijuana), Cambridge, Massachusetts